Inform Genomics and Translational Drug Development (TD2) Announce Strategic Collaboration
TD2 and Inform Genomics Announce Strategic Partnership
BOSTON, June 23, 2014 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products, and Translational Drug Development LLC (TD2) based in Scottsdale, Arizona, today announced a strategic collaboration leveraging Inform Genomics' proprietary technology platform and analytic capabilities to biopharmaceutical companies through TD2's oncology drug development services.
"We are very pleased to establish this strategic collaboration with TD2, as we see significant synergies between Inform Genomics' proprietary technology and analytics along with TD2's world-class oncology drug development service," said Ed Rubenstein, MD, President and CEO of Inform Genomics. "Developing predictive genomic-based networks of side effects of early product candidates may help identify subpopulations at risk during later stages of clinical trials."
"TD2's focus on precision oncology solutions, coupled with Inform Genomics ability to understand individual patient risk for side effects, can give a more complete vision of personalized medicine that has the opportunity to significantly improve patient care," said Stephen Gately, PhD, President and CEO of TD2.
"Having a technology to determine who will or will not develop specific types of toxicities with a particular therapy or a new agent presents a much needed new aspect of personalized medicine," said Daniel D. Von Hoff, MD, FACP, and Chief Development Officer of TD2.
Translational Drug Development (TD2) is an oncology development organization that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2's suite of capabilities provides for the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments.
For more information, visit: www.td2inc.com.
About Inform Genomics
Inform Genomics, Inc. is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development: OnPART™ and HSCT/Mucositis™ —designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. The Company's goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.
For more information, please visit www.informgenomics.com.